APOLLOHOSP
Apollo Hospitals
Apollo Hospitals (APOLLOHOSP) Stock Analysis & Case Study
Is APOLLOHOSP a good buy? The data-driven verdict.
Apollo Hospitals (APOLLOHOSP) trades at ₹8,469,on the numbers it mixed signals, a Downstox Snapshot Score of 48/100.
On the numbers, Apollo Hospitals (APOLLOHOSP) mixed signals, a Downstox Snapshot Score of 48/100, weighing expensive at 62.2× earnings, ROE of 22.1%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
APOLLOHOSP fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is APOLLOHOSP overvalued? APOLLOHOSP P/E vs its Healthcare
APOLLOHOSP's P/E of 62.2× sits above the Healthcare peer median of 17.9×, so on earnings it screens richer than peers, while its 0.22% dividend yield is below the peer median of 0.81%.
The bull case for APOLLOHOSP
- High return on equity (22.1%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
The bear case & risks
- A rich 62.2× P/E leaves a thin margin of safety if growth slows.
- A steep 12.8× price-to-book means most of the value is intangible/expectations, not assets on the books.
APOLLOHOSP Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. APOLLOHOSP scores 4/9,mixed financial health.
APOLLOHOSP MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy APOLLOHOSP with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 26.5% | 3.8× |
| Zerodha | 22.6% | 4.4× |
| Groww | 22.6% | 4.4× |
| DhanCHEAPEST | 22.0% | 4.5× |
Compare every broker on the APOLLOHOSP MTF page.
APOLLOHOSP vs peers,Healthcare comparison
About Apollo Hospitals: sector, index & market-cap context
Apollo Hospitals (APOLLOHOSP) is a large-cap NSE-listed company in the Healthcare sector, and a constituent of the Nifty 50 index group, with a market capitalisation of ₹1.22L Cr. See more Nifty 50 stocks.
How the APOLLOHOSP Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Apollo Hospitals's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
APOLLOHOSP analysis, FAQs
Is Apollo Hospitals (APOLLOHOSP) a good buy?
On the numbers, Apollo Hospitals (APOLLOHOSP) mixed signals, a Downstox Snapshot Score of 48/100, weighing expensive at 62.2× earnings, ROE of 22.1%. This is a data snapshot for research, not investment advice.
Is APOLLOHOSP overvalued or undervalued?
APOLLOHOSP trades at 62.2× earnings versus a peer median of 17.9×, so it screens richer than its Healthcare peers.
What is the bull case for APOLLOHOSP?
High return on equity (22.1%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
What are the risks in APOLLOHOSP?
A rich 62.2× P/E leaves a thin margin of safety if growth slows. A steep 12.8× price-to-book means most of the value is intangible/expectations, not assets on the books.